Matches in Wikidata for { <http://www.wikidata.org/entity/Q90358511> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q90358511 description "article scientifique publié en 2018" @default.
- Q90358511 description "artículu científicu espublizáu en xunu de 2018" @default.
- Q90358511 description "scientific article published on 01 June 2018" @default.
- Q90358511 description "wetenschappelijk artikel" @default.
- Q90358511 description "наукова стаття, опублікована в червні 2018" @default.
- Q90358511 name "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer" @default.
- Q90358511 name "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer" @default.
- Q90358511 type Item @default.
- Q90358511 label "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer" @default.
- Q90358511 label "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer" @default.
- Q90358511 prefLabel "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer" @default.
- Q90358511 prefLabel "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer" @default.
- Q90358511 P1433 Q90358511-84C648AE-E7A2-4E0D-BDD4-33A18FD63657 @default.
- Q90358511 P1476 Q90358511-0EED3FF8-8B9E-4A8C-9386-24567850D084 @default.
- Q90358511 P2093 Q90358511-0471C141-50F6-4CE9-9E42-A5340746F9CA @default.
- Q90358511 P2093 Q90358511-0E53DADC-A7C6-452A-ACC4-FEC224138648 @default.
- Q90358511 P2093 Q90358511-4E80E96F-4DB7-4835-9D0C-F46C0C9A123D @default.
- Q90358511 P2093 Q90358511-5E7115EF-B188-472F-B4DA-A3581878B01A @default.
- Q90358511 P2093 Q90358511-788E7FD0-D0C1-41E4-913F-52986419C8B1 @default.
- Q90358511 P2093 Q90358511-829917F7-231C-4EBC-B114-EF59D1A14657 @default.
- Q90358511 P2093 Q90358511-A3307CD0-0682-4F15-81F3-6E56AD3A4318 @default.
- Q90358511 P2093 Q90358511-A95F9F35-8936-4615-959E-0DF605F0D4E9 @default.
- Q90358511 P2093 Q90358511-BB90231B-25F7-4B02-960E-AA61A6D01166 @default.
- Q90358511 P2093 Q90358511-CA12AD58-8E81-42CC-95D4-86EB30BA5AB3 @default.
- Q90358511 P2093 Q90358511-CB7A6B46-367E-4F94-B134-7CDBB008D57B @default.
- Q90358511 P2093 Q90358511-D1EB5173-F066-483C-B0DF-957B59AAB49C @default.
- Q90358511 P2093 Q90358511-D2D32130-F39A-4E77-9253-53AB5EDCBB4C @default.
- Q90358511 P2093 Q90358511-D7F5E3A8-5A50-4A2C-B7C5-BF314449764A @default.
- Q90358511 P2093 Q90358511-DD178A56-05D9-422A-A1CE-C11A083ACD4F @default.
- Q90358511 P2093 Q90358511-ECDCC32A-3D06-4BF3-9FB7-9DEC68A1E703 @default.
- Q90358511 P2093 Q90358511-FBC323E7-C5FD-4E55-9418-1F364CDE711B @default.
- Q90358511 P304 Q90358511-FFB5961F-B925-4C8F-A846-F8EEC2B96174 @default.
- Q90358511 P31 Q90358511-01724C83-AF8F-4353-BDFE-504B70413352 @default.
- Q90358511 P356 Q90358511-96B63327-7105-42D3-A14C-1EF124D95285 @default.
- Q90358511 P478 Q90358511-80ACB0F4-9211-4567-A336-BFE13A247F7D @default.
- Q90358511 P577 Q90358511-73D908B4-37E7-4309-BE88-BFFC167658C9 @default.
- Q90358511 P921 Q90358511-45864699-284B-41C3-BFCF-54912CE140EE @default.
- Q90358511 P921 Q90358511-A9517638-B6CE-4FFD-8926-54189424CAEE @default.
- Q90358511 P356 MDY208.003 @default.
- Q90358511 P1433 Q326122 @default.
- Q90358511 P1476 "Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer" @default.
- Q90358511 P2093 "A Falcone" @default.
- Q90358511 P2093 "A Sobrero" @default.
- Q90358511 P2093 "A Uyei" @default.
- Q90358511 P2093 "C Eng" @default.
- Q90358511 P2093 "F Ciardiello" @default.
- Q90358511 P2093 "I Chang" @default.
- Q90358511 P2093 "J Bendell" @default.
- Q90358511 P2093 "J Tabernero" @default.
- Q90358511 P2093 "L Roberts" @default.
- Q90358511 P2093 "M Di Bartolomeo" @default.
- Q90358511 P2093 "M Fakih" @default.
- Q90358511 P2093 "M Kozloff" @default.
- Q90358511 P2093 "N Segal" @default.
- Q90358511 P2093 "N Tebbutt" @default.
- Q90358511 P2093 "T Kim" @default.
- Q90358511 P2093 "Y Shi" @default.
- Q90358511 P2093 "Y Yan" @default.
- Q90358511 P304 "v123" @default.
- Q90358511 P31 Q13442814 @default.
- Q90358511 P356 "10.1093/ANNONC/MDY208.003" @default.
- Q90358511 P478 "29 Suppl 5" @default.
- Q90358511 P577 "2018-06-01T00:00:00Z" @default.
- Q90358511 P921 Q108566365 @default.
- Q90358511 P921 Q188874 @default.